Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

129.79 -3.43 (-2.57%)
Streaming Delayed Price Updated: 1:21 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industr... 
Via StockStory
News headline image
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
From Guardant Health, Inc.
Via Business Wire
News headline image
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Growth Stocks We’re Skeptical Of
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue ↗
Via Chartmill
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Guardant Health (GH) Stock Is Down Today
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 4.1% in the afternoon session after Co-CEO AmirAli Talasaz sold 50,000 shares o... 
Via StockStory
News headline image
The Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call
Guardant Health delivered a strong start to 2026, outperforming Wall Street’s revenue expectations in Q1 as robust demand across its core oncology, biopharma... 
Via StockStory
Topics Earnings
News headline image
Guardant Health (GH) Q1 2026 Earnings Transcript ↗
Guardant Health (GH) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2026, with sales up 48.3% year on year to $301.7 million. The ... 
Via StockStory
News headline image
Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 48.3% year on year to $... 
Via StockStory
News headline image
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Earnings: What To Look For From GH
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after the bell. Here’s what you need to know. Guardant Health beat an... 
Via StockStory
News headline image
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci... 
Via StockStory
Topics Government Stocks
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou... 
Via StockStory
News headline image
Why Is Guardant Health (GH) Stock Soaring Today
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 5.9% in the afternoon session after the company announced that real-world evi... 
Via StockStory
Topics Government Stocks
News headline image
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Guardant Health (GH) Stock Is Falling Today
What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 3% in the afternoon session after major indices including the S&P 500 and Dow J... 
Via StockStory
Topics Artificial Intelligence Economy Government
News headline image
3 Growth Stocks We Think Twice About
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
News headline image
Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics
CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)... 
Via MarketMinute
Topics Supply Chain
News headline image
3 Reasons to Avoid GH and 1 Stock to Buy Instead
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 46.9%, hitting $86.90. This was partly thanks to its solid ... 
Via StockStory
Topics Supply Chain
News headline image
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.